Lomefloxacin

These indications are based on manufacturer information for both originator and generic products. For product specific registered indications, please refer to product specific manufacturer information

Registered South African indications: 

• Uncomplicated urinary tract infections (cystitis) caused by Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Staphylococcus saprophyticus
• Complicated, including recurrent, urinary tract infections caused by Citrobacter diversus, Enterobacter cloacae, Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Pseudomonas aeruginosa
• Acute exacerbation of chronic bronchitis caused by Branhamella catarrhalis, Haemophilus influenza

Contraindications

• Hypersensitivity to the active ingredient or any of its excipients
• Pregnancy
• Breastfeeding
• Severe renal impairment
• Children and growing adolescents

Cautions

• Hepatic impairment
• Exposure to direct or indirect ultraviolet light
• Known or suspected central nervous system disorders
• Epilepsy or other conditions which predispose to seizures
• May impair ability to drive and operate machinery

Forms avail. in SA and covered in this monograph: tab

Infections caused by: Gram-positive aerobic cocci (including S. saprophyticus); Gram-negative aerobic organisms (including E.coli, Klebsiella spp., Proteus mirabilis, Pseudomonas aeruginosa, H. influenzae, M. catarrhalis)

General dosing range

• Oral (tab): 400mg, dly

Specific doses based on individual indications

Please note that the dosages below should be used in combination with regional guidelines, taking into account local antibiotic sensitivities

Uncomplicated urinary tract infection

• Oral (tab): 400mg, dly; Treatment duration 3 days (Manufacturer recommendation)

Complicated urinary tract infection

• Oral (tab): 400mg, dly; Treatment duration: 10-14 days (Manufacturer recommendation)

Acute exacerbation of chronic bronchitis

• Oral (tab): 400mg, dly; Treatment duration: 7-10 days (Manufacturer recommendation)

Prophylaxis of urinary tract infection following transurethral surgery

• Oral (tab): 400mg, as a single dose 2-6 hours prior to surgery

The risk of reaction to solar ultraviolet light may be reduced by evening administration

Not established for use in children

Pregnancy

• FDA Pregnancy Category C

Breastfeeding

• Contraindicated

Renal Impairment

• Severe: Contraindicated

Hepatic Impairment

• Caution; no information available

Elderly

• No dose adjustment recommended

Central Nervous System Disorders

• Headache
• Dizziness
• Ataxia
• Seizures
• Cerebral thrombosis
• Hallucinations
• Phobia
• Central nervous system stimulation
• Drowsiness

Cardiovascular Disorders

• Cardiopulmonary arrest
• Vasculitis

Respiratory Disorders

• Laryngeal oedema
• Pulmonary oedema

Gastrointestinal Disorders

• Nausea
• Diarrhoea
• Abdominal pain
• Painful oral mucosa
• Pseudomembranous colitis

Hepatobiliary Disorders

• Hepatitis
• Elevated transaminases

Genitourinary Disorders

• Interstitial nephritis
• Polyuria
• Renal failure
• Urinary retention

Endocrine and Metabolic Disorders

• Hypoglycaemia

Musculoskeletal Disorders

• Tendinitis
• Tendon rupture

Skin and Subcutaneous Tissue Disorders

• Exfoliative dermatitis
• Hyperpigmentation
• Stevens-Johnson syndrome
• Toxic epidermal necrolysis

Immune, Blood and Lymphatic System Disorders

• Anaphylaxis
• Anaphylactoid reactions
• Haemolytic anaemia
• Leucopenia
• Myalgia

Sensory Disorders

• Diplopia
• Photophobia
• Dysgeusia

Others

• Phototoxicity

• Sucralfate
• Antacids
• Mineral supplements

None routine

Lomefloxacin interferes with the activity of the bacterial enzymes DNA gyrase and topoisomerase IV, which are vital for the transcription and replication of bacterial DNA. 

Spectrum of activity: Gram-positive aerobic cocci (including S. saprophyticus); Gram-negative aerobic organisms (including E.coli, Klebsiella spp., Proteus mirabilis, Pseudomonas aeruginosa, H. influenzae, M. catarrhalis)

Tablet 400mg

• Maxaquin (Pharmacare)